Trump administration reclassifies cannabis as Schedule III drug, easing research and financial restrictions
The Trump administration reclassified cannabis from Schedule I to Schedule III under the DEA, easing restrictions on research and allowing cannabis companies to access banking and deduct standard business expenses. This move does not legalize cannabis federally but marks a significant shift in federal policy toward recognizing its medicinal use.
Topics: Cannabis Drug Policy Financial Implications Medical Research Regulatory Reform